We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
(-9.2%)
Cap. Flow
-$15.3M
Cap. Flow
% of AUM
-0.61%
Top 10 Holdings %
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$25.7M |
| 2 |
Amgen
AMGN
|
+$24.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$19.6M |
| 4 |
uniQure
QURE
|
+$11.2M |
| 5 |
Centene
CNC
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$77.4M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$47.6M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$31.8M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$23.8M |
| 5 |
Agilent Technologies
A
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.82% |
| 2 | Consumer Staples | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
126
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.01M | 0.04% |
256,000
| – | – |
|
127
Novavax
NVAX
$1.31B
| $816K | 0.03% |
162,500
| – | – |
|
|
KLDO
128
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $753K | 0.03% |
100,050
| – | – |
|
|
KA
129
DELISTED
Kineta, Inc. Common Stock
KA
| $338K | 0.01% |
2,857
| – | – |
|
|
CVET
130
DELISTED
Covetrus, Inc. Common Stock
CVET
| $246K | 0.01% |
20,683
-11,548
| -36% | -$214K |
|
|
131
Agilent Technologies
A
$41.2B
| – | – |
-182,800
| Closed | -$13.7M |
|
132
Axogen
AXGN
$2.5B
| – | – |
-603,970
| Closed | -$12M |
|
133
CALL
Biogen
BIIB
$30.7B
| – | – |
-97,500
| Closed | -$22.8M |
|
|
134
Bristol-Myers Squibb
BMY
$132B
| – | – |
-1,050,000
| Closed | -$47.6M |
|
135
Heron Therapeutics
HRTX
$92.9M
| – | – |
-30,000
| Closed | -$558K |
|
|
ALXN
136
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-242,500
| Closed | -$31.8M |
|
|
PRAH
137
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-240,000
| Closed | -$23.8M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.
- Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
- Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
- Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
- Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
- Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
- Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
- Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.
Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.